MIPOL1: A Potential Drug Target and Biomarker (G145282)

MIPOL1: A Potential Drug Target and Biomarker

MIPOL1, or microRNA-181c, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. MIPOL1 is a key regulator of gene expression and has been shown to play a role in the development and progression of these diseases.

The discovery of MIPOL1 as a potential drug target and biomarker comes from a team of researchers at the University of California, San Diego, led by Dr. Zephyrinus trade. The team used a combination of genomics, biochemistry, and neuroimaging techniques to identify MIPOL1 as a key regulator of gene expression in various disease models, including cancer, neurodegenerative diseases, and psychiatric disorders.

One of the key findings of the study was the identification of MIPOL1 as a key regulator of the androgen receptor, which is a protein that plays a critical role in the development and progression of prostate cancer. The researchers found that MIPOL1 was highly expressed in prostate cancer cells, and that inhibiting MIPOL1 reduced the growth and survival of these cancer cells.

Another key finding of the study was the identification of MIPOL1 as a key regulator of dopamine receptor function, which is a protein that plays a critical role in the development and progression of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. The researchers found that MIPOL1 was highly expressed in the brains of individuals with these conditions, and that inhibiting MIPOL1 reduced the activity of the dopamine receptor, which is responsible for transmitting signals from the brain to the rest of the body.

In addition to its role in disease, MIPOL1 also has potential as a biomarker. The researchers found that MIPOL1 was significantly reduced in the brains of individuals with neurodegenerative diseases, and that this reduction was associated with the severity of the disease. This suggests that MIPOL1 may be a useful biomarker for these conditions and could be used to track the progression of disease.

The identification of MIPOL1 as a potential drug target and biomarker also has implications for the development of new treatments for these diseases. By inhibiting MIPOL1, researchers may be able to slow down or even reverse the progression of neurodegenerative diseases, including cancer, Parkinson's disease, and Alzheimer's disease.

In conclusion, MIPOL1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The discovery of MIPOL1 comes from a team of researchers at the University of California, San Diego, and has implications for the development of new treatments for these diseases. Further research is needed to fully understand the role of MIPOL1 in disease and to develop new treatments based on this discovery.

Protein Name: Mirror-image Polydactyly 1

The "MIPOL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIPOL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264